Fetal and Neonatal Testing, Treatment and Management Options
Managing transfusion of female children and women of childbearing age involves managing risks not present in other patient groups. Of key significance is accurate RhD typing to determine risk for anti-D.
- Between 1% and 4% of individuals have altered D antigens
- “Partial D” phenotypes or "Weak D" phenotypes
- Patient is RhD positive but may be at risk for anti-D
- Serology cannot distinguish these. RhD genotyping can determine:
- appropriate transfusion (Rh neg or Rh pos)
- candidates for Rh immune globin
Contact our lab professionals for assistance in determining the best pre-natal, fetal, and neonatal testing and management options.
RhD Genotyping Resources
- "Financial implications of RHD genotyping of pregnant women with a serologic weak D phenotype" by Kacker et al. (2015)
- "It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype" by Sandler et al. (2015)
- "How do I manage Rh typing in obstetric patients?" by Haspel et al. (2015)